InstalabLoading...
InstalabLoading...
If you have been dealing with persistently dry eyes, dry mouth, joint pain, or unexplained fatigue, the answer may be hiding in your immune system. SS-B (also called La antibody) is one of a family of autoantibodies, immune proteins that mistakenly target your own cells, that can reveal whether your body is waging a quiet war against itself.
This test is most useful when interpreted alongside its partner antibody, SS-A (also called Ro antibody). Together, they form the diagnostic foundation for identifying Sjogren's syndrome and for flagging certain forms of lupus. On its own, a positive SS-B result requires careful interpretation, because isolated SS-B positivity has limited diagnostic meaning.
SS-B is not a hormone, enzyme, or metabolite. It is an immunoglobulin, a type of protein your immune system produces. In a healthy person, immunoglobulins target foreign invaders like bacteria and viruses. In autoimmune disease, some immunoglobulins go rogue and attack your body's own tissues instead. These misdirected antibodies are called autoantibodies.
The specific target of the SS-B autoantibody is the La protein, a molecule that lives inside the nucleus (the DNA-containing center) of your cells and helps manage RNA, the molecular messenger that carries instructions from your DNA. When your immune system makes antibodies against this protein, it signals a breakdown in the normal tolerance your immune system has for your own tissues.
SS-B antibodies are produced by B cells, a type of white blood cell that has gone through abnormal activation. In people with Sjogren's syndrome, B cells become hyperactive, churning out excess antibodies. Elevated levels of a protein that helps B cells survive, called BLyS, correlate with higher SS-B levels and with the overproduction of antibodies in general.
SS-B almost never appears alone in confirmed autoimmune disease. In primary Sjogren's syndrome, SS-B was present in about 49% of patients in one cohort, but it never appeared as an isolated antibody without SS-A also being positive. The two antibodies are produced in a tightly coordinated way, driven by the same immune process, meaning they tend to rise and fall together.
When both SS-A and SS-B are positive, the combination marks a distinct subgroup of autoimmune patients: those with earlier disease onset, more glandular dysfunction (dry eyes, dry mouth), more involvement beyond the glands (joint inflammation, skin rashes, kidney involvement), higher overall antibody levels, and stronger B cell activation. This combination also connects to a pattern of overactive immune signaling called an interferon signature, which drives tissue inflammation in Sjogren's and lupus.
Here is where interpretation gets tricky, and where many non-specialists make mistakes. If your SS-B test comes back positive but your SS-A is negative, the result carries far less clinical weight. Large registry studies show that people with this SS-B positive, SS-A negative profile resemble patients who test negative for all the key autoantibodies and lack the core features of Sjogren's syndrome.
Population surveys confirm that isolated SS-B positivity is not specifically associated with any connective tissue disease. In one large routine lab survey of 624 patients, only 20% of those with isolated SS-B positivity had any connective tissue disease at all, and just 1% had primary Sjogren's. Current evidence suggests isolated SS-B should not be relied on for Sjogren's classification and may represent a weakly binding or nonspecific antibody result without clinical significance.
This distinction matters for you as someone interpreting your own results. A positive SS-B with a positive SS-A in the setting of dry eyes and dry mouth is a meaningful finding. A positive SS-B alone, without SS-A and without classic symptoms, is usually not actionable on its own.
Sjogren's syndrome is a chronic autoimmune condition in which the immune system attacks the glands that produce moisture, particularly the salivary glands and tear glands. The result is persistent dryness of the eyes and mouth, often accompanied by fatigue and joint pain. In more severe cases, the disease extends beyond the glands to affect the lungs, kidneys, nervous system, or skin.
SS-A and SS-B antibodies are considered hallmark markers for primary Sjogren's and are included in traditional diagnostic criteria. When both are present, they correlate with more active, systemic disease: higher erythrocyte sedimentation rate (ESR, a measure of how much inflammation is present), elevated antibody levels (a sign of B cell overactivity), and stronger immune signaling from interferons and B cell-stimulating proteins.
Published analyses of large Sjogren's cohorts suggest that SS-B positivity is associated with a moderately increased risk of death compared to SS-B negative patients. Other factors associated with higher mortality in Sjogren's include advanced age, male sex, parotid (salivary) gland swelling, vasculitis (inflammation of blood vessels), and low complement levels (complement proteins help the immune system clear debris and clumps of antibodies from the blood).
SS-B also appears in a subset of people with systemic lupus erythematosus (SLE, commonly called lupus), usually alongside other autoantibodies like anti-Sm, anti-RNP (ribonucleoprotein antibody), and anti-dsDNA (double-stranded DNA antibody). In adult lupus, SS-B serves more as a classification marker that helps characterize the type of lupus you have than as a measure of disease activity. Unlike anti-dsDNA, which can fluctuate with disease flares, SS-B levels tend to remain relatively stable over time.
One of the most clinically significant roles of SS-A and SS-B antibodies involves pregnancy. These maternal antibodies can cross the placenta and cause neonatal lupus in the baby. Neonatal lupus can produce a temporary rash, low blood cell counts, and liver dysfunction that typically resolve as the mother's antibodies clear from the baby's system over the first months of life.
The more serious concern is congenital heart block, an irreversible disruption of the heart's electrical conduction system. In a Finnish population study, 90% of mothers whose infants developed congenital heart block had SS-A and SS-B antibodies. The risk is highest in women with primary Sjogren's and high-level SS-A/SS-B. Cases where only SS-B is positive without SS-A are extremely rare, accounting for less than 1% of autoimmune congenital heart block. If you are pregnant or planning pregnancy and know you have these antibodies, your obstetrician should arrange fetal heart ultrasound monitoring.
SS-B antibody testing is reported as either positive or negative, sometimes with a numerical titer or index value. Most clinical laboratories use manufacturer-specific cutpoints from ELISA (a standard antibody-detection method) or similar testing platforms, and these cutpoints can differ between labs. There are no universally standardized, research-derived "optimal" or "borderline" tiers the way there are for cholesterol or blood sugar.
What matters most is the combination of your result with your SS-A status and your clinical picture. A positive SS-B with a positive SS-A and symptoms of dryness or joint pain is a meaningful pattern. A weakly positive SS-B with a negative SS-A and no symptoms is usually a finding to recheck rather than act on immediately. Always compare your results within the same lab, as switching labs can produce different values simply because of assay differences.
SS-A and SS-B antibodies can appear at low levels in healthy individuals, particularly older adults. A single weakly positive result does not confirm autoimmune disease. Low-level antinuclear antibodies (ANAs, the broader family SS-B belongs to) are relatively common in the general population and often lack diagnostic value.
No common outpatient medications (statins, metformin, blood pressure drugs, thyroid medications) are known to cause false positive SS-B results. However, immune checkpoint inhibitors (drugs that release the brakes on the immune system to fight cancer) can trigger genuine new autoantibody production, including ANAs and extractable nuclear antigens. If you are receiving cancer immunotherapy and a new SS-B positivity appears, it may reflect real drug-induced autoimmunity rather than a pre-existing condition.
Acute illness, infection, or surgery can broadly activate the immune system, but no research has established that these short-term stressors cause clinically misleading, transient SS-B positivity. Unlike some lab values that swing wildly with meals, exercise, or time of day, SS-B levels are not known to have significant time-of-day fluctuations or sensitivity to fasting or physical activity.
SS-B levels tend to be more stable over time than many other autoantibodies. In lupus cohorts, SS-B fluctuates less than anti-dsDNA or anti-Sm/RNP and is less responsive to medications that reduce B cell counts (such as rituximab). This stability means SS-B is not typically used as a real-time disease activity monitor the way anti-dsDNA might be in lupus.
That said, establishing a baseline matters. If you have a positive SS-B, confirm it with a repeat test in 3 to 6 months, especially if SS-A was negative or borderline on the first draw. If both SS-A and SS-B are confirmed positive and you have symptoms, annual monitoring alongside complement levels (C3 and C4, immune proteins that drop when autoimmune disease is active), antibody levels, and inflammatory markers can help track whether your autoimmune process is stable or evolving. A single positive result in isolation should not drive major clinical decisions.
If your SS-B and SS-A are both positive and you have symptoms like persistent dry eyes, dry mouth, joint pain, or unexplained fatigue, your next step is a rheumatology consultation. A rheumatologist can order a minor salivary gland biopsy (a small tissue sample from inside the lip) to confirm Sjogren's, assess complement levels and antibody levels to gauge disease activity, and discuss monitoring and management.
If your SS-B is positive but SS-A is negative and you have no symptoms, recheck the test in 3 to 6 months. If the isolated SS-B persists, a broader autoantibody panel (ANA with pattern and titer, anti-dsDNA, anti-Sm, anti-RNP, rheumatoid factor) can help determine whether anything else is going on. In many cases, isolated SS-B at low levels in an otherwise healthy person is a finding that requires monitoring but not immediate treatment.
If you are pregnant or planning pregnancy and have confirmed SS-A/SS-B positivity, discuss fetal heart monitoring with your obstetrician. The risk of congenital heart block is real but manageable with proper surveillance.
SS-B Antibody is best interpreted alongside these tests.